Ticker

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 223,283 shares, a growth of 20.9% from the December 15th total of 184,642 shares. Based on an average daily volume of 230,112 shares,

Trading under DCOY to commence on January 8, 2026 Company's proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX)…

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX - Get Free Report)'s stock price fell 2.6% during mid-day trading on Monday. The stock traded as low as $0.62 and last traded at $0.64. 196,853 shares changed hands during trading, a decline of 35% from the average session volume of 304,344 shares. The stock had previously closed at $0.6573.

HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual…

Salarius Pharmaceuticals (NASDAQ: SLRX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Analyst Ratings This is a breakdown of